San Diego, California — November 4, 2025 — Leads & Copy — Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) has announced interim results from its Phase 2 clinical trial of TTI-0102 for Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes or MELAS.
The trial, conducted at Radboud University in the Netherlands and CHU Angers in France, also included updates regarding its progress and planning related to its Leigh syndrome spectrum and nephropathic cystinosis clinical programs.
The interim analysis is based on the first three months of data from the Company’s placebo-controlled Phase 2 MELAS clinical trial. The trial included nine patients: six randomized to Thiogenesis’ proprietary TTI-0102 lead compound and three to placebo.
Final 6-month data from the Radboud cohort are anticipated by January 2026.
In June 2025, the U.S. Food and Drug Administration or FDA accepted Thiogenesis’ Investigational New Drug or IND application.
Encouraged by the pharmacokinetic and biomarker data for TTI-0102 in MELAS, and from previous studies, the Company plans to file an IND application for a Phase 3 pivotal clinical trial in nephropathic cystinosis.
Brook Riggins, Director and CFO, can be reached at Email: info@thiogenesis.com or Tel.: (888) 223-9165.
Source: Thiogenesis Therapeutics, Corp.
Source: Thiogenesis Therapeutics, Corp.
